Attention is focusing on whether the new tuberculosis drug Dovprela, which appeared in 50 years, can be listed on the insurance benefit list. According to related industries, Viatris Korea's Dovprela passed the HIRA Pharmaceutical Benefit Evaluation Committee on the 1st.

Dovprela, which was approved in Korea in October last year after U.S. approval in September 2019, can be used as a combination of three types of therapy with Bedaquiline and Linezolid in adult patients with extensive drug-resistant pulmonary tuberculosis, treatment-resistant or non-reactive multidrug-resistant tuberculosis. This drug is the first new treatment in more than 50 years. The TB treatment market has been shunned by front-line